CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Non-small cell lung cancer
Call For Patient Input: February 24, 2021
Patient Input Closed: April 16, 2021
Therapeutic Area: Primary hypercholesterolemia
Call For Patient Input: February 17, 2021
Patient Input Closed: April 9, 2021
Therapeutic Area: Acute myeloid leukemia
Call For Patient Input: January 29, 2021
Patient Input Closed: March 26, 2021
Therapeutic Area: Chronic sialorrhea associated with neurological disorders
Call For Patient Input: January 28, 2021
Patient Input Closed: March 19, 2021
Therapeutic Area: Acute hepatic porphyria (AHP) in adults
Call For Patient Input: January 25, 2021
Patient Input Closed: March 19, 2021
Therapeutic Area: Osteoporosis, postmenopausal women
Call For Patient Input: January 4, 2021
Patient Input Closed: February 26, 2021